-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Evommune, Lowers Price Target to $50

Benzinga·03/18/2026 11:01:26
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $65 to $50.